Reliance Global Group Inc (RELI) FinancialsRELIReliance Global Group Inc

Reliance Global Group Inc (RELI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical/Life- Altruis, accounting for 49.8% of total sales, equivalent to $2.03M. Other significant revenue streams include RELI Exchange and Medical/Life- Fortman. Understanding this composition is critical for investors evaluating how RELI navigates market cycles within the Multiline Insurance & Brokers industry.

Evaluating the bottom line, Reliance Global Group Inc maintains a gross margin of 47.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -156.80%, while the net margin is -46.34%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RELI converts its operational activities into shareholder value.

In the context of the broader market, RELI competes directly with industry leaders such as TIRX and HUIZ. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RELI's gross margin of 47.53% stands against TIRX's 100.00% and HUIZ's 27.24%. Such benchmarking helps identify whether Reliance Global Group Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue dropped to $2,495,975 (-27.47% YoY), net income improved to -$1,156,583 (up 38.13% YoY), EPS dropped to -0.2 (-70.15% YoY), and gross margin declined to 47.53% (-22.75% YoY). Overall, the financials indicate weak growth trends.